Sotorasib was administered to 2 patients with KRAS G12C (chondrosarcoma and high-grade serous adenocarcinoma derived from fallopian tube), tucatinib plus trastuzumab to 1 patient with ERBB2 amplification (ovarian clear cell adenocarcinoma), encorafenib plus binimetinib to 1 patient with BRAF V600E (thyroid papillary cancer), and FGFR2 inhibitor plus anti-PD-L1 antibody to 1 patient with FGFR2-FOXP1 gene fusion (salivary duct carcinoma). This evidence concerns the gene KRAS and ovarian clear cell adenocarcinoma.